Definition and epidemiology
Dupuytren's contracture is a benign fibroproliferative disease characterized by thickening and contracture of the palmar fascia, leading to progressive and irreversible flexion deformities of the fingers. The disorder results from abnormal myofibroblast proliferation and excessive collagen deposition in the palmar and digital fascia.
The condition shows strong geographic and ethnic predilection, being most common in populations of Northern European (particularly Scandinavian) ancestry, earning it the nickname "Viking disease." Prevalence increases dramatically with age, affecting approximately 5% of the general population but up to 30% of men over 60 years in endemic areas. The male-to-female ratio is approximately 7:1, though this gap narrows in older age groups. Onset before age 50 is associated with more aggressive disease and higher recurrence rates after treatment.
Bilateral involvement occurs in 40-60% of cases. The ring finger is most commonly affected (70-80% of cases), followed by the little finger (50-60%), middle finger (20-30%), and index finger (10-15%). Thumb involvement is rare and should raise suspicion for alternative diagnoses.
- Dupuytren's contracture most commonly affects the ring and little fingers; thumb involvement is rare
- Positive tabletop test (inability to flatten hand on table) indicates need for treatment
- Strong association with Northern European ancestry, diabetes, alcohol use, and smoking
- MCP contractures respond better to treatment than PIP contractures
- Fasciectomy has lowest recurrence rates; collagenase and needle aponeurotomy are less invasive alternatives
- Dupuytren's diathesis (early onset, bilateral disease, family history, ectopic involvement) predicts aggressive disease and higher recurrence
- Treatment indicated when MCP contracture ≥30° or any PIP contracture ≥15-20°
- Associated with Ledderhose disease (plantar fibromatosis) and Peyronie's disease (penile fibromatosis)
Etiology and risk factors
The exact etiology remains incompletely understood, but Dupuytren's contracture is considered a multifactorial disease with strong genetic and environmental components.
Genetic factors are paramount, with 60-70% of patients reporting a positive family history. The condition shows autosomal dominant inheritance with variable penetrance. Multiple genetic loci have been implicated, including genes involved in Wnt signaling pathways.
Risk factors include:
- Age: incidence increases sharply after 50 years
- Sex: male predominance (7:1 ratio)
- Ethnicity: Northern European, particularly Scandinavian descent
- Diabetes mellitus: present in 20% of patients; increases risk 3-4 fold
- Alcohol use: heavy consumption associated with higher prevalence
- Smoking: dose-dependent relationship with disease severity
- Epilepsy and anticonvulsant use: particularly phenobarbital and phenytoin
- HIV infection: higher prevalence in some studies
- Manual labor and hand trauma: controversial; likely not causative
- Family history: strongest predictor of early-onset aggressive disease
Dupuytren's diathesis describes aggressive disease characterized by early onset (before age 50), bilateral involvement, ectopic disease (Ledderhose disease of the feet, Peyronie's disease of the penis), and strong family history. These patients have higher recurrence rates after treatment.
Pathophysiology
Dupuytren's contracture results from a complex process of abnormal wound healing within the palmar fascia, progressing through three overlapping phases:
Proliferative phase
Myofibroblasts proliferate within the palmar fascia, forming cellular nodules. These specialized cells express α-smooth muscle actin and exhibit contractile properties. Growth factors including transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and connective tissue growth factor (CTGF) drive this proliferation. The nodules are the earliest clinical manifestation.
Involutional phase
Myofibroblasts align along lines of tension and begin synthesizing excessive type III collagen. The cellular nodules begin organizing into cord-like structures. This phase corresponds to the development of palpable cords without significant contracture.
Residual phase
Myofibroblast numbers decline while dense type I and III collagen deposition continues. The cords mature and contract, pulling the fingers into flexion. The metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints become progressively flexed and eventually develop secondary joint capsule contractures and skin changes.
The pathologic tissue is hypoxic, with upregulation of hypoxia-inducible factors contributing to ongoing fibroblast activation. Free radical production and oxidative stress also play roles in disease progression. Unlike normal fascia, Dupuytren's tissue shows abnormal mechanical properties and resistance to enzymatic degradation.
Clinical features
Dupuytren's contracture typically presents with slow, progressive, painless finger flexion developing over years to decades. The disease is usually asymptomatic in early stages.
Early manifestations
- Palmar nodules: firm, sometimes tender nodules in the palm, typically at the level of the distal palmar crease
- Skin pitting: dimpling or puckering of overlying palmar skin
- Palpable cords: fibrous bands extending from palm into fingers, best felt with fingers extended
Established disease
- Flexion contracture: progressive inability to fully extend affected fingers
- Positive tabletop test: inability to place the palm flat on a table with fingers extended (most important clinical sign)
- MCP joint contracture: develops first, often passively correctable early
- PIP joint contracture: develops later, more difficult to correct, causes greater functional impairment
- Skin changes: thickened, adherent palmar skin; occasionally nodules may be tender
Disease distribution
- Ring finger most commonly affected, followed by little, middle, index fingers
- Radial digits (thumb and index) rarely involved in isolation
- Bilateral in 40-60% of cases, though often asymmetric
Associated conditions (ectopic fibromatosis)
- Ledderhose disease: plantar fibromatosis of the foot (10-20% of patients)
- Peyronie's disease: penile fibromatosis (2-8% of patients)
- Knuckle pads (Garrod's pads): fibrotic thickening over PIP joints (uncommon)
The disease is generally painless unless nodules are in the proliferative phase or if secondary nerve compression develops. Functional impairment depends on which joints are affected; PIP contractures cause more disability than isolated MCP contractures.
Diagnosis
Dupuytren's contracture is a clinical diagnosis based on history and physical examination. Imaging and laboratory tests are rarely necessary.
Clinical examination
Inspection: observe for palmar nodules, skin pitting, palpable cords, and finger flexion deformity at rest. Note which rays are involved and whether disease is unilateral or bilateral.
Palpation: examine the palm and fingers for nodules and cords with the hand extended. Assess cord consistency and mobility. Check for tenderness (suggests active proliferative phase).
Tabletop test: ask patient to place palm flat on examination table with fingers extended. Inability to achieve full contact indicates significant contracture requiring consideration for treatment.
Contracture measurement: measure the passive extension deficit at each affected joint using a goniometer:
- MCP joint: normally extends to 0° (neutral)
- PIP joint: normally extends to 0° (neutral)
- Distal interphalangeal (DIP) joint: rarely affected
Functional assessment: assess impact on activities of daily living, particularly gripping objects, washing face, shaking hands, and placing hand in pockets.
Staging
Several classification systems exist; a simple functional approach:
- Grade 1: palpable nodules or cords without contracture
- Grade 2: MCP contracture < 45° or PIP contracture < 30°
- Grade 3: MCP contracture 45-90° or PIP contracture 30-60°
- Grade 4: severe contracture with MCP > 90° or PIP > 60°
Imaging
Imaging is not routinely indicated but may be used in research or preoperative planning:
- Ultrasound: can visualize nodules and cords, assess vascularity
- MRI: rarely needed; can distinguish Dupuytren's tissue from other soft tissue pathology
Laboratory studies
No specific laboratory tests diagnose Dupuytren's contracture. Consider screening for diabetes mellitus in newly diagnosed patients given the association.
Differential considerations requiring workup
If presentation is atypical (acute onset, pain, thumb involvement, ulnar-sided disease only), consider imaging to exclude other pathology such as tendon disorders, masses, or trigger finger.
Differential diagnosis
While Dupuytren's contracture is usually clinically distinctive, several conditions may mimic or coexist with it:
Trigger finger (stenosing tenosynovitis): causes catching or locking of finger flexion but with sudden release (triggering). The nodule is located over the MCP joint at the A1 pulley and moves with finger flexion. Unlike Dupuytren's, triggering is the primary complaint.
Flexor tendon disorders: tendon injuries or inflammation may limit extension but typically have acute onset, pain, and history of trauma. The inability to extend is due to tendon pathology, not fascial contracture.
Camptodactyly: congenital flexion contracture of the PIP joint, typically the little finger, present from childhood. Bilateral and non-progressive. No palmar nodules or cords.
Diabetic cheiroarthropathy: bilateral thickening of palmar skin with limited joint mobility in multiple fingers ("prayer sign"). Skin changes are more diffuse without discrete cords. Associated with long-standing diabetes.
Ulnar nerve palsy: causes clawing of ring and little fingers from weakness of intrinsic hand muscles. Patients can passively extend the MCP joints fully. Sensory deficits in ulnar distribution.
Volkmann's contracture: ischemic contracture of forearm flexor muscles following compartment syndrome. History of trauma, involves all fingers and wrist, with muscle tenderness and pain.
Rheumatoid arthritis: may cause finger deformities but with joint inflammation, pain, morning stiffness, and systemic features. Nodules are subcutaneous and over bony prominences.
Palmar fibromatosis (localized): benign soft tissue tumors (giant cell tumor, lipoma) may present as palmar masses but lack the characteristic cord formation and progressive contracture.
Reflex sympathetic dystrophy (CRPS): can cause finger stiffness following injury but with pain, swelling, temperature changes, and trophic skin changes.
Management
Management of Dupuytren's contracture is individualized based on disease severity, progression rate, functional impairment, and patient preferences. Not all patients require intervention.
Indications for treatment
The traditional Hueston's criteria indicate treatment when:
- MCP joint contracture ≥ 30°
- Any PIP joint contracture ≥ 15-20°
- Positive tabletop test (inability to flatten hand)
- Functional impairment in daily activities
Early or mild disease (nodules without contracture, MCP contracture < 30°) typically warrants observation with annual follow-up.
Non-operative management
Observation: appropriate for early disease without functional limitation. Patient education about disease natural history and recurrence risk is important.
Physical therapy and splinting: no proven efficacy in preventing progression or improving contracture. Post-treatment splinting may help maintain correction after surgical or enzymatic release.
Steroid injection: intralesional corticosteroid injection into painful nodules may reduce tenderness in the proliferative phase but does not prevent progression or treat contracture.
Radiotherapy: low-dose radiation therapy has been used in Europe for early disease to slow progression but is not standard practice in the United States due to concerns about long-term effects and lack of high-quality evidence.
Minimally invasive procedures
Needle aponeurotomy (percutaneous fasciotomy): office-based procedure using a needle to puncture and divide cords. Advantages include minimal recovery time and lower cost. Disadvantages include higher recurrence rates (50-70% at 5 years) and risk of neurovascular injury. Best for isolated MCP contractures.
Collagenase injection: injectable collagenase Clostridium histolyticum enzymatically digests collagen in Dupuytren's cords. Office injection followed 24-48 hours later by manipulation to rupture the cord. Efficacy similar to surgery for MCP contractures but less effective for PIP contractures. Recurrence rates intermediate between needle aponeurotomy and surgery. Use with caution in patients with coagulation disorders or on anticoagulants.
Surgical management
Fasciectomy remains the gold standard, with lowest long-term recurrence rates (20-40% at 5 years).
Limited (segmental) fasciectomy: removal of affected fascia only. Most common approach, balances efficacy with morbidity.
Regional fasciectomy: removal of all palmar fascia in affected ray. Used for extensive or recurrent disease.
Dermofasciectomy: excision of fascia and overlying skin with skin grafting. Reserved for severe recurrent disease or when skin is severely involved. Lowest recurrence rate.
Fasciotomy: simple division of cord without excision. Higher recurrence but useful in elderly or high-risk surgical patients.
Postoperative care
Includes wound care, hand elevation, early mobilization, and splinting (night extension splinting for 3-6 months). Hand therapy is crucial for optimizing outcomes.
Treatment selection
Choice depends on patient factors (age, comorbidities, occupation), disease factors (joints involved, severity, recurrence), and available expertise:
- Single-digit MCP contracture: collagenase or needle aponeurotomy often preferred
- PIP contracture: fasciectomy generally superior
- Multiple digits or severe disease: fasciectomy
- Recurrent disease: dermofasciectomy may be needed
- High surgical risk patients: needle aponeurotomy
Management of recurrence
Recurrence is common (20-50% depending on treatment). Options include repeat fasciectomy, dermofasciectomy, or amputation in severe cases affecting a single digit.
Guidelines from the American Academy of Orthopaedic Surgeons and British Society for Surgery of the Hand support individualized treatment selection, with surgery remaining the standard for definitive correction of significant contractures.
Complications and prognosis
Complications of the disease
Progressive contracture: without treatment, contractures typically worsen over years. PIP contractures progress more rapidly than MCP contractures and are less responsive to treatment once established.
Secondary joint changes: chronic contracture leads to capsular fibrosis, collateral ligament shortening, and articular cartilage changes, making complete correction impossible even with surgery.
Skin changes: chronic contracture causes skin shortening and adherence to underlying fascia, complicating surgical treatment.
Functional impairment: severe contractures interfere with gripping objects, hand hygiene, and activities requiring flat palm contact.
Treatment complications
Surgical complications (fasciectomy):
- Neurovascular injury: 2-5% risk, including digital nerve and artery injury
- Wound complications: delayed healing, dehiscence, infection (5-10%)
- Hematoma: 1-3%
- Complex regional pain syndrome: rare but serious
- Digital necrosis: rare but devastating complication from vascular compromise
- Loss of flexion: "flare reaction" with reflex sympathetic dystrophy features
Needle aponeurotomy complications:
- Skin tears: 5-10%
- Nerve injury: transient numbness in 5% (usually resolves)
- Tendon rupture: rare but reported
Collagenase injection complications:
- Peripheral edema and bruising: nearly universal, resolves in days
- Skin tears: 10-15% during manipulation
- Tendon rupture: < 1%, particularly flexor tendons
- Complex regional pain syndrome: rare
- Allergic reactions: rare; antibody formation may preclude repeat treatment
Recurrence
Recurrence is the major long-term limitation of all treatments. Rates vary by treatment modality:
- Fasciectomy: 20-40% at 5 years
- Collagenase: 30-50% at 3-5 years
- Needle aponeurotomy: 50-70% at 5 years
Risk factors for recurrence include younger age at onset, Dupuytren's diathesis (early onset, bilateral disease, ectopic fibromatosis, family history), PIP joint involvement, and incomplete initial correction.
Prognosis
Dupuytren's contracture is a benign condition that does not affect life expectancy but can significantly impact quality of life. Disease progression is variable:
- Some patients have stable disease for years
- Others experience rapid progression, particularly those with diathesis features
- PIP contractures have worse prognosis than MCP contractures
- Treatment can improve function but does not cure the disease
Patients with Dupuytren's diathesis should be counseled about the high likelihood of recurrence and potential need for multiple treatments over their lifetime. Despite treatment limitations, most patients achieve meaningful functional improvement and satisfaction with intervention.
Practice questions
1. A 62-year-old man of Scandinavian descent presents with progressive inability to fully extend his right ring finger over the past 2 years. He has type 2 diabetes and a 30-pack-year smoking history. Examination reveals a palpable cord in the palm extending to the ring finger, and the patient cannot place his palm flat on the examination table. The metacarpophalangeal joint has a 35° flexion contracture. What is the most appropriate next step in management?
2. A 55-year-old man undergoes successful limited fasciectomy for Dupuytren's contracture affecting his left little finger. Three years later, he returns with recurrent contracture of the same digit with 25° PIP joint flexion deformity. His father and brother both had bilateral Dupuytren's disease before age 50. On examination, he also has firm nodules on the plantar aspect of both feet. Which feature most strongly predicts his prognosis?
3. A 68-year-old woman presents with a 1-year history of a painless lump in her palm and difficulty straightening her ring finger. She has well-controlled type 2 diabetes. Examination reveals a 20° MCP joint contracture of the ring finger with a palpable palmar cord. She reports no functional limitations in daily activities. What is the most appropriate management?
Frequently asked questions
What causes Dupuytren's contracture?
Dupuytren's contracture is caused by abnormal proliferation of myofibroblasts and excessive collagen deposition in the palmar fascia. The exact cause is unknown, but it has strong genetic components with 60-70% of patients having a family history. Risk factors include Northern European ancestry, male sex, age over 50, diabetes mellitus, smoking, and heavy alcohol use. The condition is not caused by hand trauma or manual labor, though these were historically suspected.
What are the first symptoms of Dupuytren's contracture?
The first symptom is typically a painless firm nodule or lump in the palm, usually near the base of the ring or little finger at the distal palmar crease. The overlying skin may become dimpled or puckered. Over months to years, a cord-like thickening develops extending from the palm into the finger, eventually causing the finger to bend toward the palm. Most patients notice difficulty fully straightening the affected finger before experiencing functional limitations.
How is Dupuytren's contracture diagnosed?
Dupuytren's contracture is diagnosed clinically through physical examination without need for imaging or laboratory tests. The key diagnostic features are palpable palmar nodules and cords with progressive finger flexion contracture. The tabletop test, where the patient cannot place the palm flat on a table with fingers extended, is the most important clinical sign. A goniometer is used to measure the degree of contracture at each joint to guide treatment decisions.
Is Dupuytren's contracture curable?
Dupuytren's contracture is not curable; all treatments address symptoms rather than eliminating the underlying disease process. Surgical removal of affected tissue (fasciectomy) provides the longest-lasting correction but has 20-40% recurrence at 5 years. Less invasive options like collagenase injection or needle aponeurotomy have higher recurrence rates (30-70%). The condition tends to recur because the genetic and biochemical factors driving abnormal fibroblast activity persist after treatment. Multiple treatments may be needed over a patient's lifetime.
Dupuytren's contracture vs trigger finger — what is the difference?
Dupuytren's contracture causes a permanent flexion deformity from palmar fascia thickening, with palpable cords and inability to fully extend the finger even passively. Trigger finger causes the finger to catch or lock during flexion then suddenly release (trigger), due to tendon nodule catching on the A1 pulley. In trigger finger, the nodule moves with finger motion and is located over the MCP joint, while Dupuytren's cords are fixed in the palm. Trigger finger causes pain and clicking; Dupuytren's is usually painless.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: M72.0
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.